These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 37437135)

  • 1. Long-Term Follow-Up of Patients with Scleritis After Rituximab Treatment Including B Cell Monitoring.
    van Bilsen K; Vergouwen DPC; van Velthoven MEJ; Missotten TOAR; Rombach SM; van Zelm MC; Berkowska MA; van Hagen PM; Kuijpers RWAM; van Laar JAM
    Ocul Immunol Inflamm; 2024 Sep; 32(7):1268-1273. PubMed ID: 37437135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab in the treatment of refractory scleritis in patients with granulomatosis with polyangiitis (Wegener's).
    Recillas-Gispert C; Serna-Ojeda JC; Flores-Suárez LF
    Graefes Arch Clin Exp Ophthalmol; 2015 Dec; 253(12):2279-84. PubMed ID: 26507398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term Outcomes of Rituximab Therapy in Ocular Granulomatosis with Polyangiitis: Impact on Localized and Nonlocalized Disease.
    Joshi L; Tanna A; McAdoo SP; Medjeral-Thomas N; Taylor SR; Sandhu G; Tarzi RM; Pusey CD; Lightman S
    Ophthalmology; 2015 Jun; 122(6):1262-8. PubMed ID: 25745876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab Induction and Maintenance Treatment in Patients with Scleritis and Granulomatosis with Polyangiitis (Wegener's).
    You C; Ma L; Lasave AF; Foster CS
    Ocul Immunol Inflamm; 2018; 26(8):1166-1173. PubMed ID: 28628344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab in the Treatment of Refractory Noninfectious Scleritis.
    Cao JH; Oray M; Cocho L; Foster CS
    Am J Ophthalmol; 2016 Apr; 164():22-8. PubMed ID: 26766304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subconjunctival Rituximab Administration for the Treatment of Scleritis.
    Vergouwen DPC; Ten Berge JC; Naus-Postema NC; Rothova A
    Ocul Immunol Inflamm; 2022 Aug; 30(6):1309-1311. PubMed ID: 35171758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab therapy for refractory idiopathic scleritis.
    Bogdanic-Werner K; Fernandez-Sanz G; Alejandre Alba N; Ferrer Soldevila P; Romero-Bueno FI; Sanchez-Pernaute O
    Ocul Immunol Inflamm; 2013 Aug; 21(4):329-32. PubMed ID: 23662782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti B-cell therapy against refractory thrombocytopenia in SLE and MCTD patients: long-term follow-up and review of the literature.
    Jovancevic B; Lindholm C; Pullerits R
    Lupus; 2013 Jun; 22(7):664-74. PubMed ID: 23612795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relapse of nephrotic syndrome during post-rituximab peripheral blood B-lymphocyte depletion.
    Sato M; Kamei K; Ogura M; Ishikura K; Ito S
    Clin Exp Nephrol; 2018 Feb; 22(1):110-116. PubMed ID: 28434126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides.
    Venhoff N; Effelsberg NM; Salzer U; Warnatz K; Peter HH; Lebrecht D; Schlesier M; Voll RE; Thiel J
    PLoS One; 2012; 7(5):e37626. PubMed ID: 22629432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclophosphamide or Rituximab Treatment of Scleritis and Uveitis for Patients with Granulomatosis with Polyangiitis.
    Ahmed A; Foster CS
    Ophthalmic Res; 2019; 61(1):44-50. PubMed ID: 29635229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Consolidation Treatment and Long-Term Prognosis of Rituximab in Minimal Change Disease and Focal Segmental Glomerular Sclerosis.
    Lin L; Wang W; Wu Y; Xie J; Li X; Pan X; Zhang W; Xu J; Cai Y; Ren H; Chen N
    Drug Des Devel Ther; 2021; 15():1945-1953. PubMed ID: 34007154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab as Induction Therapy in Eosinophilic Granulomatosis with Polyangiitis Refractory to Conventional Immunosuppressive Treatment: A 36-Month Follow-Up Analysis.
    Thiel J; Troilo A; Salzer U; Schleyer T; Halmschlag K; Rizzi M; Frede N; Venhoff A; Voll RE; Venhoff N
    J Allergy Clin Immunol Pract; 2017; 5(6):1556-1563. PubMed ID: 28916432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome).
    Thiel J; Hässler F; Salzer U; Voll RE; Venhoff N
    Arthritis Res Ther; 2013 Sep; 15(5):R133. PubMed ID: 24286362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low pre-treatment B-cell counts are not a risk factor of infection in patients treated with rituximab for autoimmune diseases: An observational study.
    Lazarou I; Finckh A; Fischer L; Ribi C; Gascon D; Seebach JD; Guerne PA
    Joint Bone Spine; 2016 Mar; 83(2):191-7. PubMed ID: 26677998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab therapy for refractory scleritis: results of a phase I/II dose-ranging, randomized, clinical trial.
    Suhler EB; Lim LL; Beardsley RM; Giles TR; Pasadhika S; Lee ST; de Saint Sardos A; Butler NJ; Smith JR; Rosenbaum JT
    Ophthalmology; 2014 Oct; 121(10):1885-91. PubMed ID: 24953794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of relapse and long-term outcome in children with steroid-dependent nephrotic syndrome after rituximab treatment.
    Fujinaga S; Hirano D; Mizutani A; Sakuraya K; Yamada A; Sakurai S; Shimizu T
    Clin Exp Nephrol; 2017 Aug; 21(4):671-676. PubMed ID: 27558467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the Response to Rituximab between Myelin Oligodendrocyte Glycoprotein and Aquaporin-4 Antibody Diseases.
    Durozard P; Rico A; Boutiere C; Maarouf A; Lacroix R; Cointe S; Fritz S; Brunet C; Pelletier J; Marignier R; Audoin B
    Ann Neurol; 2020 Feb; 87(2):256-266. PubMed ID: 31725931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Highly Sensitive Flow Cytometric Detection of Residual B-Cells After Rituximab in Anti-Neutrophil Cytoplasmic Antibodies-Associated Vasculitis Patients.
    van Dam LS; Oskam JM; Kamerling SWA; Arends EJ; Bredewold OW; Berkowska MA; van Dongen JJM; Rabelink TJ; van Kooten C; Teng YKO
    Front Immunol; 2020; 11():566732. PubMed ID: 33384685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New immunomodulators in the treatment of Graves' ophthalmopathy.
    Salvi M; Vannucchi G; Campi I; Currò N; Beck-Peccoz P
    Ann Endocrinol (Paris); 2008 Apr; 69(2):153-6. PubMed ID: 18417090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.